

To

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001

Suo moto

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release issued by the Company on the captioned subject, the content of which is self-explanatory.

This is for your information and record please.

Thanking you,

Yours faithfully,
For

(Neha Vaishnav)

March 06, 2024

Suo moto

It has been noticed that there are certain news articles circulating in the mainstream media about an entity manufacturing and selling spurious and counterfeit medicines under the name and style of Nectar Herbs and Drugs (“accused”) based in Uttarakhand. Recently they have been apprehended and action is initiated against the accused as per media reports.

In this regard, it is hereby clarified that the Nectar Lifesciences Limited (“Company”) or its Directors or Promoters or Key Managerial Personnel or employees, have absolutely no relation/ connection/ association or link of any nature with the Nectar Herbs and Drugs. The Company is neither the supplier, customer, investor of the accused nor sharing any management or facility or knowhow with it. While various regulatory and law enforcing agencies are investigating and taking appropriate action against the accused, the Company is also in process of taking legal advice for appropriate legal recourse against the accused in this regard.

The Company is clarifying about this information out of abundant precaution and alert and caution investors, customers, suppliers and the general public at large about such firms/ companies/ entities/ persons, the names of which resemble with the name of the Company.

Nectar Lifesciences Ltd. (NLL) is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. NLL has today emerged as top ranked organization amongst mid-sized pharmaceutical companies in India as per “Fortune Next 500” 2017 & is among top 40 fore runners of the Bio-Pharmaceutical industry in Asia-Pacific Region as per “Bio-Spectrum Asia Pacific” 2016 besides being one of the top amongst Indian API manufacturers.

NLL has transformed itself from being a domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. NLL currently has a strong hold of API & Formulation business in almost 45 countries of the world. with 11 State of Art manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels. NLL is a public listed company with stocks being traded on BSE and NSE.